Drug Delivery Systems for Metabolic Disorders

1. Introduction to metabolic disorders 2. Cellular and molecular mechanisms involved in metabolic disorders 3. Current practices in drug delivery for metabolic disorders 4. Recent developments towards treatment of amyloidosis. 5. Advanced drug delivery systems targeting to improve therapeutic outcomes in Porphyria 6. Advanced drug delivery systems targeting Kwashiorkor involving disturbance in protein metabo-lism 7. Advanced drug delivery systems targeting metabolic disorders involving a disturbance in protein metabolism: Erythropoietic Uroporphyria. 8. Combating Atherosclerosis with novel drug delivery approaches: From benchside to commerciali-zation 9. Advanced drug delivery systems in the management of Gaucher Disease 10. Advanced drug delivery systems focusing the metabolic disorders due to deregulation of lipid me-tabolism: Niemann Pick Disease & Letterer-Siwe disease 11. Novel Drug Delivery system to treat Niemann-Pick disease 12. Novel 3D printing drug delivery system for the prevention and treatment of Atherosclerosis 13. Advanced drug delivery systems to treat Huntington disease: Challenges and opportunities 14. Advanced Drug Delivery Systems for obesity 15. Advanced drug delivery systems probing the metabolic disorder due to deregulation in carbohy-drate metabolism 16. Advanced drug delivery systems dealing with metabolic disorder due to disturbance in hormone metabolism- hypoglycaemia and hyperglycemia, 17. EMERGING drug delivery in the treatment of hyperpituitarism and hypopituitarism 18. Advanced drug deliver system dealing with metabolisn disorders due to disturbance in harmone metabolism example Hypoparathyroidism and Hyperparathyroidism 19. An update on development of advanced drug delivery systems for treatment of hyperthyroidism 20. Advanced drug delivery systems involving lysosomal storage disorders for Schinder disease and other disorders 21. Advanced drug delivery systems involving lysosomal storage disorders for Fabry disease 22. Drug delivery systems in Krabbe Disease: Present and prospective approaches. 23. Advanced Treatment Strategies to combat Tay-Sachs Disease (TSD) 24. Sandhoff Disease: Pathology and Advanced Treatment Strategies 25. Nanomaterial-based drug delivery approaches for metabolic disorders. 26. Eye in Metabolic Disorders: Manifestations and Drug Delivery Systems 27. Advanced drug delivery systems involving mitochondrial disorders 28. Application of phytoceuticals in targeting metabolic disorders 29. Phytonanoparticles towards the treatment of diabetes. 30. Role of Neutraceuticals in metabolic disorders 31. Latest Advances of phytomedicine in drug delivery systems for targeting metabolic disorders. 32. Clinical trials, future prospects and challenges of drug delivery in combating metabolic disorders

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Indústria farmacêutica
• Farmacologia

3D printing; AMPK; Acid sphingomyelinase; Advance drug delivery systems; Advanced drug delivery; Advanced drug delivery system; Advanced drug delivery systems; Amyloid fibrillation; Amyloidosis; Anti-thyroid drugs; Antioxidants; Atherosclerosis; Autosomal; Blood glucose; Blood-brain barrier; Bone Marrow Transplantation (BMT); Bone marrow transplantation; Brain targeted drug delivery; Cardiovascular disease; Cataract; Cellulose; Challenges; Clinical trials; Curcumin; Delivery systems; Dendrimers; Diabetes; Diabetes mellitus; Diabetic retinopathy; Diagnosis; Drug delivery; Drug delivery systems; Dysadaptation; Dyslipidemia; Endocrine; Enhanced drug efficacy; Enhanced gene therapy; ss-Hexosaminidase; ss-glucocerebrosidase; Enzyme replacement therapy; Erythropoietic uroporphyria; Extracellular vesicles; Fabry disease; Free radical damage; GM2-gangliosidosis; GM2-gangliosidosis; Galactosylceramide (GalCer); Galactosylcerebrosidase (GALC); Galactosylsphingosine (psychosine); Gaucher disease; Gene therapy; Genetics; Glaucoma; Globoid cell leukodystrophy; Heme-biosynthesis; Hepatotoxicity; Histiocytes; Hormone replacement therapy; Huntington's diseases; Hyperglycemia; Hyperpituitarism; Hyperthyroidism; Hypoglycemia; Hypopituitarism; Immunotherapy; Improve therapeutic outcomes; Inflammation; Inherited metabolic disorders; Insulin; Insulin resistance; Intraocular pressure; Iodides; JAK-STAT; Krabbe disease; Leptin; Letterer Siwe disease; Lignin; Liposomes; Lysosomal disorder-inherited metabolic disorder; Lysosomal storage; Lysosomal storage diseases; Lysosomal storage disorders; Lysosome-cellular component; Macronutrients; Magnetically controlled drug delivery system; Malnutrition; Metabolic; Metabolic diseases; Metabolic disorders; Metabolic syndrome; Metabolism; Metformin; Microbiome; Microganglia; Microneedles; Miglustat; Mitochondrial disorders; Multipotent; NPD Type -2; NPD Type-1